Thermo Fisher Scientific (TMO) Non-Current Deferred Tax Liability (2009 - 2026)

Thermo Fisher Scientific has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $2.1 billion for Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 102.4% year-over-year to $2.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 102.4% YoY) and the FY2025 annual result came in at $1.5 billion, up 17.74% from the prior year.
• Non-Current Deferred Tax Liability advanced to $2.1 billion in Q1 2026, from $1.5 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $3.5 billion in Q2 2022 and troughed at $624.0 million in Q2 2025.
• A 5-year average of $2.1 billion and a median of $1.9 billion in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability jumped 114.33% — and 2025, when it sank 58.84%.
• Tracing TMO's Non-Current Deferred Tax Liability over 5 years: stood at $2.8 billion in 2022, then sank by 32.54% to $1.9 billion in 2023, then tumbled by 34.03% to $1.3 billion in 2024, then advanced by 17.74% to $1.5 billion in 2025, then soared by 41.13% to $2.1 billion in 2026.
• Business Quant data shows TMO's Non-Current Deferred Tax Liability at $2.1 billion in Q1 2026, $1.5 billion in Q4 2025, and $842.0 million in Q3 2025.